Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinkyo Yoon

Showing results (21-30 of 88) with videos related to

Pageof 9
Sort By:
Annals of Laboratory Medicine|October 16, 2020
Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean PatientsJa Young Seo, Jeong-Yeal Ahn, Bhumsuk Keam, et al.
Oncotargets and Therapy|August 24, 2019
Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrationsHo Cheol Kim, Yeh Rim Kang, Wonjun Ji, et al.
Lung Cancer (Amsterdam, Netherlands)|July 12, 2022
Clinicopathologic and genomic features of high-grade pattern and their subclasses in lung adenocarcinomaBokyung Ahn, Shinkyo Yoon, Deokhoon Kim, et al.
Cancer Research and Treatment|May 6, 2021
The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by SurgeryHyehyun Jeong, Kye Jin Park, Yongjune Lee, et al.
JAMA Network Open|March 24, 2021
Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysisHyo Jung Park, Kyung Won Kim, Sang Eun Won, et al.
Journal of Cancer Research and Clinical Oncology|June 25, 2016
Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancerShinkyo Yoon, Byung Woog Kang, Su Yeon Park, et al.
Cancer Research and Treatment|March 28, 2019
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean PatientsYeonjoo Choi, Bhumsuk Keam, Miso Kim, et al.
Cancer Research and Treatment|February 17, 2025
A Multicenter Phase II Study of Modified FOLFIRINOX for First-line Treatment for Advanced Urachal Cancer (ULTMA; KCSG GU20-03)Inkeun Park, Jae Lyun Lee, Shinkyo Yoon, et al.
Korean Journal of Radiology|September 28, 2025
State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder CancerSarah Eid, Abdullah S Al-Yousef, Kyung Won Kim, et al.
Translational Lung Cancer Research|July 23, 2021
Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective studyMyeong Geun Choi, Chang-Min Choi, Dae Ho Lee, et al.
Pageof 9

Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
Annals of Laboratory Medicine|October 16, 2020
Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean PatientsJa Young Seo, Jeong-Yeal Ahn, Bhumsuk Keam, et al.
Oncotargets and Therapy|August 24, 2019
Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrationsHo Cheol Kim, Yeh Rim Kang, Wonjun Ji, et al.
Lung Cancer (Amsterdam, Netherlands)|July 12, 2022
Clinicopathologic and genomic features of high-grade pattern and their subclasses in lung adenocarcinomaBokyung Ahn, Shinkyo Yoon, Deokhoon Kim, et al.
Cancer Research and Treatment|May 6, 2021
The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by SurgeryHyehyun Jeong, Kye Jin Park, Yongjune Lee, et al.
JAMA Network Open|March 24, 2021
Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysisHyo Jung Park, Kyung Won Kim, Sang Eun Won, et al.
Journal of Cancer Research and Clinical Oncology|June 25, 2016
Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancerShinkyo Yoon, Byung Woog Kang, Su Yeon Park, et al.
Cancer Research and Treatment|March 28, 2019
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean PatientsYeonjoo Choi, Bhumsuk Keam, Miso Kim, et al.
Cancer Research and Treatment|February 17, 2025
A Multicenter Phase II Study of Modified FOLFIRINOX for First-line Treatment for Advanced Urachal Cancer (ULTMA; KCSG GU20-03)Inkeun Park, Jae Lyun Lee, Shinkyo Yoon, et al.
Korean Journal of Radiology|September 28, 2025
State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder CancerSarah Eid, Abdullah S Al-Yousef, Kyung Won Kim, et al.
Translational Lung Cancer Research|July 23, 2021
Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective studyMyeong Geun Choi, Chang-Min Choi, Dae Ho Lee, et al.
Pageof 9